{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:46:23Z","timestamp":1781045183032,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biogen Int GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40801-024-00459-6","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T03:41:06Z","timestamp":1728531666000},"page":"573-591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03662919","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-4274","authenticated-orcid":false,"given":"Bruno","family":"Fautrel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5787-4943","authenticated-orcid":false,"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-4161","authenticated-orcid":false,"given":"Carine","family":"Salliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4779-5168","authenticated-orcid":false,"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin","family":"Fumery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-2902","authenticated-orcid":false,"given":"Christophe","family":"Bernardeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5131-8524","authenticated-orcid":false,"given":"Yves","family":"Maugars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-7046","authenticated-orcid":false,"given":"Mathurin","family":"Flamant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9175-8620","authenticated-orcid":false,"given":"Fabienne","family":"Coury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7378-1034","authenticated-orcid":false,"given":"Ben","family":"Braithwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima","family":"Hateb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the PERFUSE investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"459_CR1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","volume":"21","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021;21:680\u20136. https:\/\/doi.org\/10.1038\/s41577-021-00603-1.","journal-title":"Nat Rev Immunol"},{"key":"459_CR2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13075-019-1980-1","volume":"21","author":"H-H Chen","year":"2019","unstructured":"Chen H-H, Chao W-C, Chen Y-H, Hsieh T-Y, Lai K-L, Chen Y-M, et al. Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study. Arthritis Res Ther. 2019;21:196. https:\/\/doi.org\/10.1186\/s13075-019-1980-1.","journal-title":"Arthritis Res Ther"},{"key":"459_CR3","doi-asserted-by":"publisher","first-page":"175628482110066","DOI":"10.1177\/17562848211006669","volume":"14","author":"G Privitera","year":"2021","unstructured":"Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, et al. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Ther Adv Gastroenterol. 2021;14:17562848211006668. https:\/\/doi.org\/10.1177\/17562848211006669.","journal-title":"Ther Adv Gastroenterol"},{"key":"459_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.680043","volume":"12","author":"S Shams","year":"2021","unstructured":"Shams S, Martinez JM, Dawson JRD, Flores J, Gabriel M, Garcia G, et al. The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol. 2021;12: 680043. https:\/\/doi.org\/10.3389\/fphar.2021.680043.","journal-title":"Front Pharmacol"},{"key":"459_CR5","volume-title":"Adalimumab","author":"CR Ellis","year":"2022","unstructured":"Ellis CR, Azmat CE. Adalimumab. StatPearls: StatPearls Publishing; 2022."},{"key":"459_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.dld.2021.08.020","volume":"54","author":"A Vitello","year":"2022","unstructured":"Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, et al. Effectiveness of adalimumab for ulcerative colitis: a multicentre, retrospective study of clinical practice in Italy. Dig Liver Dis. 2022;54:352\u20137. https:\/\/doi.org\/10.1016\/j.dld.2021.08.020.","journal-title":"Dig Liver Dis"},{"key":"459_CR7","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279\u201389. https:\/\/doi.org\/10.1002\/art.21306.","journal-title":"Arthritis Rheum"},{"key":"459_CR8","doi-asserted-by":"publisher","unstructured":"Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10:iii\u2013iv, xi\u2013xiii, 1\u2013229. https:\/\/doi.org\/10.3310\/hta10420.","DOI":"10.3310\/hta10420"},{"key":"459_CR9","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1007\/s12325-019-00986-7","volume":"36","author":"D Patel","year":"2019","unstructured":"Patel D, Shelbaya A, Cheung R, Aggarwal J, Park SH, Coindreau J. Cost-effectiveness of early treatment with originator biologics or their biosimilars after methotrexate failure in patients with established rheumatoid arthritis. Adv Ther. 2019;36:2086\u201395. https:\/\/doi.org\/10.1007\/s12325-019-00986-7.","journal-title":"Adv Ther"},{"key":"459_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001016","volume":"5","author":"B Glintborg","year":"2019","unstructured":"Glintborg B, Ibsen R, Bilbo REQ, Hetland ML, Kjellberg J. Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis. RMD Open. 2019;5: e001016. https:\/\/doi.org\/10.1136\/rmdopen-2019-001016.","journal-title":"RMD Open"},{"key":"459_CR11","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40744-022-00465-6","volume":"9","author":"RCS van Adrichem","year":"2022","unstructured":"van Adrichem RCS, Voorneveld HJE, Waverijn GJ, Kok MR, Bisoendial RJ. The non-medical switch from reference adalimumab to biosimilar adalimumab is highly successful in a large cohort of patients with stable inflammatory rheumatic joint diseases: a real-life observational study. Rheumatol Ther. 2022;9:1109\u201318. https:\/\/doi.org\/10.1007\/s40744-022-00465-6.","journal-title":"Rheumatol Ther"},{"key":"459_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/annrheumdis-2015-eular.1419","volume":"74","author":"D Shin","year":"2015","unstructured":"Shin D, Kim Y, Kim HS, Fuhr R, K\u00f6rnicke T. FRI0110 a phase I pharmacokinetic study comparing SB5, an adalimumab biosimilar, and adalimumab reference product (Humira\u00ae) in healthy subjects. Ann Rheum Dis. 2015;74:459\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2015-eular.1419.","journal-title":"Ann Rheum Dis"},{"key":"459_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/art.40336","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Jaworski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70:40\u20138. https:\/\/doi.org\/10.1002\/art.40336.","journal-title":"Arthritis Rheumatol"},{"key":"459_CR14","doi-asserted-by":"publisher","first-page":"iv49","DOI":"10.1093\/rheumatology\/kex276","volume":"56","author":"T Uhlig","year":"2017","unstructured":"Uhlig T, Goll GL. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford). 2017;56:iv49\u201362. https:\/\/doi.org\/10.1093\/rheumatology\/kex276.","journal-title":"Rheumatology (Oxford)"},{"key":"459_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2018t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44\u20138. https:\/\/doi.org\/10.1002\/art.1780380107.","journal-title":"Arthritis Rheum"},{"key":"459_CR16","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker J-C, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954\u201360. https:\/\/doi.org\/10.1136\/ard.2007.084459.","journal-title":"Ann Rheum Dis"},{"key":"459_CR17","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"459_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/s0140-6736(80)92767-1","volume":"1","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s-disease activity. Lancet. 1980;1:514. https:\/\/doi.org\/10.1016\/s0140-6736(80)92767-1.","journal-title":"Lancet"},{"key":"459_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/gut.43.1.29","volume":"43","author":"RS Walmsley","year":"1998","unstructured":"Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29\u201332. https:\/\/doi.org\/10.1136\/gut.43.1.29.","journal-title":"Gut"},{"key":"459_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000382","volume":"3","author":"RM Fleischmann","year":"2017","unstructured":"Fleischmann RM, van der Heijde D, Gardiner PV, Szumski A, Marshall L, Bananis E. DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open. 2017;3: e000382. https:\/\/doi.org\/10.1136\/rmdopen-2016-000382.","journal-title":"RMD Open"},{"issue":"2","key":"459_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1080\/00365520310000654","volume":"38","author":"SL Jowett","year":"2003","unstructured":"Jowett SL, Seal CJ, Phillips E, et al. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol. 2003;38(2):164\u201371. https:\/\/doi.org\/10.1080\/00365520310000654.","journal-title":"Scand J Gastroenterol"},{"key":"459_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12865-021-00473-1","volume":"22","author":"F Francois","year":"2021","unstructured":"Francois F, Naimi L, Roblin X, Berger A-E, Paul S. Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501). BMC Immunol. 2021;22:81. https:\/\/doi.org\/10.1186\/s12865-021-00473-1.","journal-title":"BMC Immunol"},{"key":"459_CR23","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1093\/ecco-jcc\/jjab100","volume":"15","author":"LAAP Derikx","year":"2021","unstructured":"Derikx LAAP, Dolby HW, Plevris N, Lucaciu L, Rees CS, Lyons M, et al. Effectiveness and safety of adalimumab biosimilar SB5 in inflammatory bowel disease: outcomes in originator to SB5 switch, double biosimilar switch and Bio-Na\u00efve SB5 observational cohorts. J Crohn\u2019s Colitis. 2021;15:2011\u201321. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab100.","journal-title":"J Crohn\u2019s Colitis"},{"key":"459_CR24","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/00365521.2022.2041082","volume":"57","author":"M Lukas","year":"2022","unstructured":"Lukas M, Kolar M, Reissigova J, Duricova D, Machkova N, Hruba V, et al. A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn\u2019s disease: an analysis of two propensity score-matched cohorts. Scand J Gastroenterol. 2022;57:814\u201324. https:\/\/doi.org\/10.1080\/00365521.2022.2041082.","journal-title":"Scand J Gastroenterol"},{"key":"459_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25092","author":"G Haugeberg","year":"2023","unstructured":"Haugeberg G, Bakland G, R\u00f8devand E, Hansen IJW, Diamantopoulos A, Pripp AH. Effectiveness and persistence in SB4- and reference etanercept-treated rheumatoid arthritis patients in ordinary clinical practice in Norway. Arthritis Care Res. 2023. https:\/\/doi.org\/10.1002\/acr.25092.","journal-title":"Arthritis Care Res"},{"key":"459_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.crohns.2012.03.016","volume":"7","author":"E McDermott","year":"2013","unstructured":"McDermott E, Murphy S, Keegan D, O\u2019Donoghue D, Mulcahy H, Doherty G. Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis. 2013;7:150\u20133. https:\/\/doi.org\/10.1016\/j.crohns.2012.03.016.","journal-title":"J Crohns Colitis"},{"key":"459_CR27","doi-asserted-by":"publisher","first-page":"1759720X2110336","DOI":"10.1177\/1759720X211033679","volume":"13","author":"C Bruni","year":"2021","unstructured":"Bruni C, Gentileschi S, Pacini G, Bardelli M, Tofani L, Bartoli F, et al. Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211033679. https:\/\/doi.org\/10.1177\/1759720X211033679.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"459_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3899\/jrheum.200609","volume":"49","author":"MM Khraishi","year":"2022","unstructured":"Khraishi MM, Remple VP, Silverberg S, Stewart JC, Florica B, Bessette L. Canadian adalimumab postmarketing observational epidemiological study assessing effectiveness in psoriatic arthritis (COMPLETE-PsA): 12-month results of comparative effectiveness of adalimumab and nbDMARDs. J Rheumatol. 2022;49:454\u201364. https:\/\/doi.org\/10.3899\/jrheum.200609.","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"459_CR29","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1136\/annrheumdis-2022-eular.2358","volume":"81","author":"U M\u00fcller-Ladner","year":"2022","unstructured":"M\u00fcller-Ladner U, Gaffney K, Jadon D, Freudensprung U, Addison J, et al. AB0348: the PROPER study: a 48-week analysis of a pan-EU real-world study of SB5 biosimilar following transition from reference adalimumab in patients with rheumatoid arthritis, axial spondyloarthritis or psoriatic arthritis. Ann Rheum Dis. 2022;81(Suppl 1):1299\u2013300.","journal-title":"Ann Rheum Dis"},{"key":"459_CR30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10620-018-5329-4","volume":"64","author":"A Sartini","year":"2019","unstructured":"Sartini A, Scaioli E, Liverani E, Bellanova M, Ricciardiello L, Bazzoli F, et al. Retention rate, persistence and safety of adalimumab in inflammatory bowel disease: a real-life, 9-year, single-center experience in Italy. Dig Dis Sci. 2019;64:863\u201374. https:\/\/doi.org\/10.1007\/s10620-018-5329-4.","journal-title":"Dig Dis Sci"},{"key":"459_CR31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/apt.16478","volume":"54","author":"A Blesl","year":"2021","unstructured":"Blesl A, Binder L, H\u00f6genauer C, Wenzl H, Borenich A, Pregartner G, et al. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther. 2021;54:667\u201377. https:\/\/doi.org\/10.1111\/apt.16478.","journal-title":"Aliment Pharmacol Ther"},{"key":"459_CR32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.51821\/85.4.10724","volume":"85","author":"N Deprez","year":"2022","unstructured":"Deprez N, De Somer T, Baert D, Deceuninck M, Huys I, Mattens V, et al. Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting. AGEB. 2022;85:557\u201364. https:\/\/doi.org\/10.51821\/85.4.10724.","journal-title":"AGEB"},{"key":"459_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","volume":"7","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, Jairath V, Mysler E, Nicholls D, Declerck P. Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology? Rheumatol Ther. 2020;7:35\u201364. https:\/\/doi.org\/10.1007\/s40744-019-00190-7.","journal-title":"Rheumatol Ther"},{"key":"459_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","volume":"7","author":"A St Clair-Jones","year":"2020","unstructured":"St Clair-Jones A, Prignano F, Goncalves J, Paul M, Sewerin P. Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatol Ther. 2020;7:741\u201357. https:\/\/doi.org\/10.1007\/s40744-020-00245-0.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"459_CR35","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s40259-023-00616-3","volume":"37","author":"U M\u00fcller-Ladner","year":"2023","unstructured":"M\u00fcller-Ladner U, Dignass A, Gaffney K, Jadon D, Matucci-Cerinic M, Lobaton T, et al. The PROPER study: a 48-week, Pan-European, real-world study of biosimilar SB5 following transition from reference adalimumab in patients with immune-mediated inflammatory disease. BioDrugs. 2023;37(6):873\u201389. https:\/\/doi.org\/10.1007\/s40259-023-00616-3.","journal-title":"BioDrugs"},{"key":"459_CR36","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/annrheumdis-2021-220202","volume":"80","author":"E Vallejo-Yag\u00fce","year":"2021","unstructured":"Vallejo-Yag\u00fce E, Keystone EC, Kandhasamy S, Micheroli R, Finckh A, Burden AM. Primary and secondary non-response: in need of operational definitions in observational studies. Ann Rheum Dis. 2021;80:961\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220202.","journal-title":"Ann Rheum Dis"},{"key":"459_CR37","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/bcp.15101","volume":"88","author":"N Garc\u00eda-Beloso","year":"2022","unstructured":"Garc\u00eda-Beloso N, Altab\u00e1s-Gonz\u00e1lez I, Samart\u00edn-Ucha M, Gayoso-Rey M, De Castro-Parga ML, Salgado-Barreira \u00c1, et al. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: a systematic literature review. Br J Clin Pharmacol. 2022;88:1529\u201350. https:\/\/doi.org\/10.1111\/bcp.15101.","journal-title":"Br J Clin Pharmacol"},{"key":"459_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fmed.2019.00234","volume":"6","author":"M Mastronardi","year":"2019","unstructured":"Mastronardi M, Curlo M, Cavalcanti E, Burattini O, Cuppone R, Tauro R, et al. Administration timing is the best clinical outcome predictor for adalimumab administration in Crohn\u2019s disease. Front Med (Lausanne). 2019;6:234. https:\/\/doi.org\/10.3389\/fmed.2019.00234.","journal-title":"Front Med (Lausanne)"},{"key":"459_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89790-4","author":"L Cingolani","year":"2021","unstructured":"Cingolani L, Barberio B, Zingone F, Ferronato A, Bertani L, Costa F, et al. Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. Sci Rep. 2021. https:\/\/doi.org\/10.1038\/s41598-021-89790-4.","journal-title":"Sci Rep"},{"key":"459_CR40","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gut.2005.069476","volume":"55","author":"S Vermeire","year":"2006","unstructured":"Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426\u201331. https:\/\/doi.org\/10.1136\/gut.2005.069476.","journal-title":"Gut"},{"key":"459_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key075.462","author":"A Blyth","year":"2018","unstructured":"Blyth A, Simmonds O, Blackler L, Kirkham B, Ng N, Cope A, et al. 238 biologic dose optimisation in clinical practice. Rheumatology. 2018. https:\/\/doi.org\/10.1093\/rheumatology\/key075.462.","journal-title":"Rheumatology"},{"key":"459_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/cpt.2253","volume":"111","author":"GE Simon","year":"2022","unstructured":"Simon GE, Platt R, Watanabe JH, Bindman AB, John London A, Horberg M, et al. When can we rely on real-world evidence to evaluate new medical treatments? Clin Pharmacol Ther. 2022;111:30\u20134. https:\/\/doi.org\/10.1002\/cpt.2253.","journal-title":"Clin Pharmacol Ther"},{"key":"459_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.05.025","author":"Y Bouhnik","year":"2023","unstructured":"Bouhnik Y, Carbonnel F, Fumery M, et al. The PERFUSE study: the experience of patients receiving adalimumab biosimilar SB5. Digest Liver Dis. 2023. https:\/\/doi.org\/10.1016\/j.dld.2023.05.025.","journal-title":"Digest Liver Dis."}],"updated-by":[{"DOI":"10.1007\/s40801-024-00477-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000}}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-024-00459-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T06:22:11Z","timestamp":1737094931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-024-00459-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["459"],"URL":"https:\/\/doi.org\/10.1007\/s40801-024-00459-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40801-024-00477-4","asserted-by":"object"}]},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"26 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40801-024-00477-4","URL":"https:\/\/doi.org\/10.1007\/s40801-024-00477-4","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Biogen Int GmbH (Baar, Switzerland). Funding was provided by Biogen. Open access fees were sponsored by Biogen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Bruno Fautrel: received speaker\/consulting fees from AbbVie, Biogen, Boehringer Ingelheim, BMS, Celgene, Janssen, Lilly, Medac, MSD, NORDIC Pharma, Novartis, Pfizer, Roche, Sobi and UCB, and grant\/research support from AbbVie, MSD and Pfizer. Yoram Bouhnik: received consultancy and\/or speaker fees from AbbVie, Biogaran, Biogen, Boehringer Ingelheim, CTMA, Ferring, Gilead, Hospira, ICON, Inception IBD, Janssen, Lilly, Mayoly Spindler, Merck, Merck Sharp & Dohme, Norgine, Pfizer, Robarts Clinical Trials, Roche, Sanofi, Shire, Takeda, UCB and Vifor Pharma. Carine Salliot: received consultancy and\/or speaker fees from Novartis, Roche-Chugai, Pfizer and Galapagos, and grant\/research support from Roche-Chugai and Novartis. Frank Carbonnel: received speaker fees from Abbvie, Astra, Biocodex, Biogen, Ferring, Janssen, MSD, Pfizer, Pileje, Takeda, Tillotts; and is a member of advisory boards for Amgen, Arena, BMS, Celltrion, Enterome, Ferring, Janssen, Medtronic, Pfizer, Pharmacosmos, Roche and Tillotts. Mathurin Fumery: received consultancy and\/or speaker fees from AbbVie, Biogen, Boehringer Ingelheim, CTMA, Ferring, Gilead, Hospira, Janssen, Lilly, Merck Sharp & Dohme, Pfizer, Takeda, Tillots and Celgene. Chirstophe Bernardeau: nothing to disclose with respect to their contributions to this work. Yves Maugars: nothing to disclose with respect to their contributions to this work. Mathurin Flamant: received consultancy and\/or speaker fees from AbbVie, Amgen, Biogen, Ferring, Janssen, Mayoly Spindler, Merck Sharp & Dohme, Pfizer, Takeda, Tillots and Pharma. Fabienne Coury: received speaker\/consulting fees from Abbvie, Amgen, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, Roche-Chugai, Sanofi and UCB, and grant\/research support from Abbvie, Biogen, Celgene, Chugai, Novartis, Pfizer and UCB. Ben Braithwaite: no conflicts of interest to disclose. Salima Hateb: is an employee of and may hold stock in Biogen. Janet Addison: is an employee of and may hold stock in Biogen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated and analysed during the current study are not publicly available as data for this study contain potentially identifying information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All necessary ethical considerations and measures were taken to ensure the protection of all participants: patients were eligible for the study only if they were able to understand and sign a consent form. This study is listed on clinicaltrials.gov under the identifier NCT03662919 and was approved by the appropriate bodies in terms of quality of methodology, data security and scientific merit. The final amendment to the protocol for this study was approved by an independent ethics committee (Comit\u00e9 de Protection des Personnes, CPP) in France on 25 April 2019, in accordance with French regulations (CPP SUD-EST II; study ref. 2018-06; internal ref. 19.03.29.73319). Furthermore, this study conformed to all regulations concerning the use of personal data. All procedures were carried out in accordance with the ethical rules and the principles of the Declaration of Helsinki and its later amendments.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study in the form of a non-opposition form signed and archived by the physician in accordance with French regulations.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The code used to perform data management and run the analyses uses proprietary modules owned by eXYSTAT. Thus, the code cannot be made publicly available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Bruno Fautrel: as the coordinating investigator for rheumatology, made substantial contributions to the conception and design of the work, the acquisition and interpretation of data for the work and reviewed all draft versions of the manuscript for important intellectual content. Yoram Bouhnik: as the coordinating investigator for gastroenterology, made substantial contributions to the conception and design of the work, the acquisition and interpretation of data for the work and reviewed all draft versions of the manuscript for important intellectual content. Carine Salliot: as an investigator, made substantial contributions to the acquisition and interpretation of data for the work and reviewed all draft versions of the manuscript for important intellectual content. Mathurin Fumery: as an investigator, made substantial contributions to the acquisition and interpretation of data for the work and reviewed all draft versions of the manuscript for important intellectual content. Chirstophe Bernardeau: as an investigator, made substantial contributions to the acquisition and interpretation of data for the work and reviewed all draft versions of the manuscript for important intellectual content. Mathurin Flamant: as an investigator, made substantial contributions to the acquisition and interpretation of data for the work and reviewed all draft versions of the manuscript for important intellectual content. Fabienne Coury: as an investigator, made substantial contributions to the acquisition and interpretation of data for the work and reviewed all draft versions of the manuscript for important intellectual content. Ben Braithwaite: as the lead writer and biostatistics coordinator for this work, made substantial contributions to the design of the work, acquisition, analysis and interpretation of data for the work and produced all draft versions of the manuscript. Salima Hateb: as a study coordinator for the sponsor, made substantial contributions to the conception and design of the work, the acquisition and interpretation of data for the work and reviewed all draft versions of the manuscript for important intellectual content. Janet Addison: as the sponsor\u2019s lead scientist for this work, made substantial contributions to the conception and design of the work, the analysis and interpretation of data for the work and critically reviewed, commented upon and edited all draft versions of the manuscript. The first draft of the manuscript was written by Ben Braithwaite and all authors commented on previous versions of the manuscript. All authors read, provided input and approved the final manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}